Trial reportAlzheimer's & dementia : the journal of the Alzheimer's Association2013
Amyloid positron emission tomography with (18)F-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer's disease.
Trial report in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Implications for Management of PET Amyloid Classification Technology
Implications for Management of PET Amyloid Classification Technology in the Imaging Dementia(IDEAS) Trial
Who cites it
35 citing papers in PubMed, 60 citations in OpenAlex.
- Unraveling Alzheimer's complexity with a distinct AβNature chemical biology · 2026Article
- Development and Implementation of a Radiation Safety Screening Protocol for a Clinical Study Using Amyloid Positron Emission Tomography Imaging.Ochsner journal · 2026Article
- Change in brain glucose metabolism and cognition in amnestic MCI patients in relation to amyloid accumulation: A 3-year follow-up study.Aging brain · 2026Article
- Distinct Characteristics of Suspected Non-Alzheimer Pathophysiology in Relation to Cognitive Status and Cerebrovascular Burden.Clinical nuclear medicine · 2025Article
- Quantitative Imaging of Regional Cerebral Protein Synthesis in Clinical Alzheimer's Disease by [Molecular imaging and biology · 2024Article
- Targeting amyloid proteins for clinical diagnosis of neurodegenerative diseases.Fundamental research · 2023Review
- Change in brain amyloid load and cognition in patients with amnestic mild cognitive impairment: a 3-year follow-up study.EJNMMI research · 2022Article
- Associations Between Vascular Risk Factors and Perivascular Spaces in Adults with Intact Cognition, Mild Cognitive Impairment, and Dementia.Journal of Alzheimer's disease : JAD · 2022Article
- Network-wise concordance of multimodal neuroimaging features across the Alzheimer's disease continuum.Alzheimer's & dementia (Amsterdam, Netherlands) · 2022Article
- A Gaussian-based model for early detection of mild cognitive impairment using multimodal neuroimaging.Journal of neuroscience methods · 2020Article
- Visual Object Discrimination Impairment as an Early Predictor of Mild Cognitive Impairment and Alzheimer's Disease.Journal of the International Neuropsychological Society : JINS · 2019Article
- Innovative Molecular Imaging for Clinical Research, Therapeutic Stratification, and Nosography in Neuroscience.Frontiers in medicine · 2019Review
- A biomarker study in long-lasting amnestic mild cognitive impairment.Alzheimer's research & therapy · 2018Article
- Longitudinal outcomes of amyloid positive versus negative amnestic mild cognitive impairments: a three-year longitudinal study.Scientific reports · 2018Article
- Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment.Alzheimer's research & therapy · 2018Article
- Review
- Selecting the most relevant brain regions to discriminate Alzheimer's disease patients from healthy controls using multiple kernel learning: A comparison across functional and structural imaging modalities and atlases.NeuroImage. Clinical · 2018Article
- Neuropsychology and neuroimaging profiles of amyloid-positive versus amyloid-negative amnestic mild cognitive impairment patients.Alzheimer's & dementia (Amsterdam, Netherlands) · 2018Article
- Cerebrospinal fluid neurogranin/β-site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease.Alzheimer's & dementia (New York, N. Y.) · 2018Article
- Amyloid Positivity Using [18F]Flutemetamol-PET and Cognitive Deficits in Nondemented Community-Dwelling Older Adults.American journal of Alzheimer's disease and other dementias · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveTo evaluate the contributions of amyloid-positive (Am+) and medial temporal atrophy-positive (MTA+) scans to the diagnostic classification of prodromal and probable Alzheimer's disease (AD).
methods(18)F-flutemetamol-labeled amyloid positron emission tomography (PET) and magnetic resonance imaging (MRI) were used to classify 10 young normal, 15 elderly normal, 20 amnestic mild cognitive impairment (aMCI), and 27 AD subjects. MTA+ status was determined using a cut point derived from a previous study, and Am+ status was determined using a conservative and liberal cut point.
resultsThe rates of MRI scans with positive results among young normal, elderly normal, aMCI, and AD subjects were 0%, 20%, 75%, and 82%, respectively. Using conservative cut points, the rates of Am+ scans for these same groups of subjects were 0%, 7%, 50%, and 93%, respectively, with the aMCI group showing the largest discrepancy between Am+ and MTA+ scans. Among aMCI cases, 80% of Am+ subjects were also MTA+, and 70% of amyloid-negative (Am-) subjects were MTA+. The combination of amyloid PET and MTA data was additive, with an overall correct classification rate for aMCI of 86%, when a liberal cut point (standard uptake value ratio = 1.4) was used for amyloid positivity.
interpretation(18)F-flutemetamol PET and structural MRI provided additive information in the diagnostic classification of aMCI subjects, suggesting an amyloid-independent neurodegenerative component among aMCI subjects in this sample.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.